AVZO-021 + palbociclib + letrozole

AVZO-021 + palbociclib + letrozole is an investigational combination therapy under clinical evaluation for the treatment of advanced solid tumors, particularly hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. AVZO-021 is a selective and potent cyclin-dependent kinase 2 (CDK2) inhibitor, currently in phase 1/2 trials as both a monotherapy and in combination with other agents. Palbociclib is a well-established oral CDK4/6 inhibitor, while letrozole is an aromatase inhibitor used in hormonal therapy. The combination aims to target cell cycle progression via dual inhibition of CDK2 and CDK4/6, alongside blockade of estrogen synthesis, to overcome resistance mechanisms and enhance antitumor efficacy in HR+/HER2- breast cancer. The primary developer for AVZO-021 is Avenzo Therapeutics[2][7]. Palbociclib is developed and marketed by Pfizer, and letrozole by Novartis. The route of administration for all three agents in the combination is oral[4][7].